SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001819790-24-000050
Filing Date
2024-04-23
Accepted
2024-04-23 08:34:44
Documents
16
Period of Report
2024-04-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tars-20240419.htm   iXBRL 8-K 34456
2 EX-99.1 exhibit991-refinancedebt.htm EX-99.1 6450
6 GRAPHIC exhibit991-refinancedebt001.jpg GRAPHIC 191955
7 GRAPHIC exhibit991-refinancedebt002.jpg GRAPHIC 191412
  Complete submission text file 0001819790-24-000050.txt   702718

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tars-20240419.xsd EX-101.SCH 1892
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tars-20240419_lab.xml EX-101.LAB 22530
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tars-20240419_pre.xml EX-101.PRE 13037
19 EXTRACTED XBRL INSTANCE DOCUMENT tars-20240419_htm.xml XML 2929
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39614 | Film No.: 24862781
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)